Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.
Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need. Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including cardiometabolic and fibrotic complications.
INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversago’s lead program.
Dr. Glenn Crater, CMO at Inversago, stated: “This IND clearance is an important milestone for Inversago and marks the beginning of an important regulatory and clinical process in bringing a new therapeutic approach to patients suffering from Diabetic Kidney Disease.”
“We are excited to report this significant achievement for our first-in-class, peripherally-acting CB1 inverse agonist, which confirms our leadership in this field. We believe that CB1 blockers, such as INV-202, offer opportunities in multiple therapeutic areas,” added François Ravenelle, PhD, Chief Executive Officer of Inversago.
Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including Diabetic Kidney Disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs.
About Diabetic Kidney Disease
Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease. Like other chronic diseases, it is expected that multiple mechanisms are needed to achieve adequate control of this progressive disease. Inversago believes that peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. For more information, visit inversago.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005424/en/
Contact information
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.
info@inversago.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran and GLDS integrate Mosaic CP with BroadHub ® for enhanced broadband service billing and management3.5.2024 14:00:00 CEST | Press release
Adtran today announced that GLDS’s customer management and billing platform, BroadHub®, is now integrated with Adtran’s Mosaic CP and its SDX Series of optical line terminals (OLTs). Building on a longstanding partnership, the collaboration enhances automated service management by enabling instantaneous adjustments to network conditions and rapid responses to customer demands. It promises to boost service capabilities and operational efficiencies for service providers globally, offering advanced scalability for growing networks and real-time data analytics for improved service management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240503338277/en/ Adtran’s partnership with GLDS is helping service providers simplify customer management and streamline billing processes. (Photo: Business Wire) “Our strategic partnership with Adtran is driven by a shared commitment to empowering service providers with robust customer managem
Sampled Named One of the First Olink ® Certified Service Providers3.5.2024 13:59:00 CEST | Press release
Sampled1 today announced that it has been named one of the first Olink®Certified Service Providers Olink’s state-of-the-art proteomics technology enables understanding of complex biological pathways and disease markers. Proteomics technology is an important tool for studying diseases, providing crucial insights into their underlying molecular mechanisms. The consistent and highly accurate results produced by Olink's Proximity Extension Assay (PEA) technology have made it widely recognized and extensively cited in various research fields for protein profiling and biomarker development. Olink® Certified Service Providers are recognized for their commitment to delivering the highest quality standards, undergoing rigorous training and annual certification using concordance samples. “We are proud to be one of the first Olink®Certified Service Providers and believe it highlights our dedication to pioneering health innovations. With this technology we can empower our clients with cutting-edge
KLDiscovery Takes Steps to Strengthen Balance Sheet and Long-Term Financial Foundation2.5.2024 22:30:00 CEST | Press release
KLDiscovery Inc. (“KLDiscovery” or the “Company”), a global leader in data management, information governance, eDiscovery, and advisory services solutions, today announced that it has reached an agreement in principle with its principal convertible debenture holders and its principal term loan lender to significantly reduce the Company’s long-term debt and strengthen its financial position, enabling KLDiscovery to focus on its growth model and drive investment in its market-leading client solutions. “Today’s announcement marks an important step forward for our company as we move into the future with a capital structure that supports our industry-leading team and long-term growth and profitability objectives,” said Chris Weiler, Chief Executive Officer of KLDiscovery. “KLDiscovery is a strong business with a leading market position, premier brands, and a clear vision for the future. This agreement underscores our key capital partners’ belief in that vision and will provide our company w
SES AI Reports First Quarter 2024 Earnings Results; Affirms 2024 Outlook2.5.2024 22:15:00 CEST | Press release
SES AI Corporation (“SES AI”) (NYSE: SES), a global leader in the development and manufacturing of high-performance Li-Metal batteries, today announced its first quarter 2024 business results for the period ended March 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502964429/en/ The Company posted a Letter to Our Shareholders on its Investor Relations website from Founder and CEO Dr. Qichao Hu and Chief Financial Officer Jing Nealis, which provides a business update and details on first quarter 2024 results. “The game-changing collaboration with Hyundai Motor Company and Kia Corporation is one of the more significant milestones we have reached to date,” stated Dr. Qichao Hu, Founder and CEO. “Moving to the next phase of our contract with these partners, together with other agreements and UAM cell production we are anticipating later this year, reinforces our lead in the race to commercialize our Li-Metal technol
The Indy Autonomous Challenge Returns to the Indianapolis Motor Speedway on September 6, 20242.5.2024 20:00:00 CEST | Press release
The Indy Autonomous Challenge (IAC) will make a grand return to the Indianapolis Motor Speedway (IMS) “The Racing Capital of the World” on September 6th, 2024. The competition is set to be a landmark event, featuring a head-to-head race of the world’s fastest autonomous racecars piloted by AI driver software developed by 10 teams representing 18 top universities from North America, Europe, and Asia. History was made at IMS in October 2021 when IAC organized the world’s first head-to-head high-speed autonomous racing competition. Since then, IAC has organized five races at iconic tracks, including Las Vegas Motor Speedway during CES and the Monza F1 Circuit in Italy. IAC and its university teams have achieved a long list of world records for high-speed ground-based autonomy. World records include the autonomous land speed record (192.2 mph), the top speed on-track (180 mph), the fastest on-track head-to-head overtake (177 mph), and most miles of autonomous racing (7,500 miles). “Three y